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Abstract: Nanoparticles are widely studied as carrier vehicles in 
biological systems because their size readily allows access through 
cellular membranes. Moreover, they have the potential to carry cargo 
molecules and as such, these factors make them especially attractive 
for intravenous drug-delivery purposes. Interest in protein-based 
nanoparticles has recently gained attraction due to particle 
biocompatibility and lack of toxicity. However, the production of 
homogeneous protein nanoparticles with high encapsulation 
efficiencies, without the need for additional cross-linking or further 
engineering of the molecule, remains challenging. Here, we present a 
microfluidic 3D co-flow device to generate human serum 
albumin/celastrol nanoparticles by co-flowing an aqueous protein 
solution with celastrol in ethanol. This micro-scale co-flow method 
resulted in the formation of nanoparticles with a homogeneous size 
distribution and an average size, which could be tuned from »100 nm 
to 1 µm by modulating the flow rates used. We show that the high 
stability of the particles stems from the covalent cross-linking of the 
naturally present cysteine residues within the particles formed during 
the assembly step. By choosing optimal flow rates during synthesis 
an encapsulation efficiency of 75 ± 24% was achieved. Finally, we 
show that this approach achieves significantly enhanced solubility of 
celastrol in the aqueous phase and, crucially, reduced cellular toxicity. 
Targeted delivery and controllable release of active 
pharmaceuticals are major objectives to improve the safety and 
efficacy of potential drugs. These important properties can be 
enhanced by using suitable drug carriers, such as nanoparticles. 
Nanoparticles are an attractive class of carrier in this context 
because they can solubilize therapeutic cargo, which can prolong 
the circulation lifetimes of drugs and ability to extravasate to 
tumour sites.1 These therapeutic cargo carriers need to be very 
biocompatible to decrease the risk of unwanted complications 
Thus, protein nanoparticles, which intrinsically have minimal 
immunogenicity and biocompatibility, have attracted a lot of 
interest.2 An additional benefit of using proteins for nanoparticle 
formation is that they can be selectively modified with specific 
ligands for targeting purposes.3 Previously, proteins have been 
applied to increase stability in microdroplets4 to form protein-
based nanoparticles from bovine serum albumin (BSA),5 human 
serum albumin (HSA)6 and β-lactoglobulin7. Interestingly, albumin 
nanoparticles have been shown to penetrate through the blood-
brain barrier,8 which broadens the areas where therapeutic 
agents could be delivered. 
There are a wide variety of methods available for nanoparticle 
formation, which includes nano emulsification and spray drying.9 
However, these methods require chemical cross-linking or 
proteins to form fibrillar networks. Another, popular method for 
nanoparticle formation is desolvation, in which a protein or 
polymer is in aqueous media and a desolvating agent, such as 
ethanol, is added drop by drop.10 In this method the introduction 
of the desolvating agent to the protein solution, de-stabilises the 
protein structure and exposes its buried hydrophobic and reactive 
residues. This promotes interactions between protein molecules, 
so that the proteins clump together in small aggregate 
nanoparticles.11 Recently, a method to introduce intermolecular 
disulfide bonds between HSA molecules to avoid the use of toxic 
crosslinkers.12 This approach relied on an additional denaturing 
step prior to nanoparticle formation, which reduced some of the 
HSA’s disulfide bridges and further promoted cysteine-cysteine 
interactions between different HSA molecules during nanoparticle 
formation.  
Here, we present a microfluidic co-flow strategy for 
nanoparticle formation without the need for additional crosslinkers. 
This co-flow method is based on the desolvation method, but 
instead of dropwise addition, the desolvating agent flows adjacent 
to the protein solution in a microfluidic chip. In this approach, 
mixing is much faster with no gradual increase of the desolvating 
agent concentration. Furthermore, we encapsulated a highly 
lipophilic drug, celastrol, into HSA nanoparticles. Celastrol is a 
natural compound extracted from the herb, tripterygium wilfordii, 
a direct modulator of progesterone and cannabinoid receptors13 
that elicits a potent anti-inflammatory response14 and shows 
promise as a treatment for Alzheimer’s disease,14 obesity,15 
rheumatoid arthritis16 and cancer.17 Due to its hydrophobicity, 
celastrol is difficult to use in aqueous solutions. Therefore, it would 
be a significant advance if this molecule could be encapsulated 
into a more hydrophilic shell. With our approach, we show 
encapsulation of celastrol with high efficiency within HSA 
nanoparticles, which increases celastrol’s solubility and 
simultaneously dramatically decreases its cytotoxicity. 
To showcase the variety of this co-flow method to produce 
nanoparticles, we initially investigated the formation of BSA 
nanoparticles by using ethanol as the desolvating agent. BSA was 
introduced from the middle inlet and surrounded by ethanol 
(Figure 1a and 1b). Additionally, a water stream was added as 
the outer layer. This water layer has two purposes: 
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Figure 1. Microfluidic co-flow device design. Schematic representation of the 
microfluidic co-flow method for synthesis protein nanoparticles. (a) CAD design 
from the co-flow device, in which water flows from the outer channel, ethanol 
from the middle channel, and protein from the inner channel. (b) The three 
solutions meet in the middle of the device to form the nanoparticle. (c) The 3D 
channel geometry gives co-flow layers. 
first, the water pinches the ethanol and protein stream so that 
there will be fast diffusion between the streams. Secondly, the 
water layer will ensure that the protein does not come in contact 
with the hydrophobic polydimethylsiloxane (PDMS) walls to avoid 
surface adherance. To completely envelop the protein and 
ethanol streams with water a 3D co-flow design was used (Figure 
1c). In a conventional 2D microfluidic chip the fluid streams flow 
adjacent to one another, whereas in 3D devices one stream flow 
within the another (Figure 1c).  
Our 3D co-flow device was applied to study BSA nanoparticle 
formation with two different concentrations and six different flow 
rates were used to study. Figure 2 shows the size distributions 
measured with dynamic light scattering (DLS; Figures 2a and 2d) 
and average diameters (Figures 2b and 2e) from BSA 
nanoparticles prepared from 1 mg/mL (Figures 2a and 2b) and 
10 mg/mL (Figures 2d and 2e) BSA solutions. This study 
revealed that whilst the concentration has only a limited effect on 
the average size, it has a larger effect on the size distributions. 
Furthermore, polydispersity in the nanoparticle samples produced 
with a 10 mg/mL BSA solution was larger showing an increase in 
recorded polydispersity indexes (PDI; Table S1). This is also 
evident from the DLS size distributions for which broader peaks 
are observed (Figure 2d). Furthermore, larger standard 
deviations were recorded for the average diameters (Figure 2e). 
A more profound effect was achieved by changing the EtOH to 
protein flow-rate ratio. The higher the EtOH flow rate, the higher 
the concentration of EtOH in the resulting mixture, and 
subsequently the bigger the nanoparticles formed. With 1 mg/mL 
BSA solution the average size increases exponentially. However, 
in the case of 10 mg/mL BSA solution, the increase in average 
diameter is more linear. This can be explained by the 10-fold 
increase of protein molecules as the EtOH concentration remains 
constant. Thus, the curve is shifted to the right as BSA 
concentration is increased. The morphology of BSA nanoparticles 
was examined by transmission electron microscopy (TEM). 
Figure 2 shows BSA nanoparticles made from 1 mg/mL (Figure 
2c parts i and ii) and 10 mg/mL solutions (Figure 2f parts i and 
ii), using a 1:1 flow ratio. The particles were highly spherical for 
both protein concentrations. However, based on the TEM 
micrographs the polydispersity seems to be larger in the case of 
nanoparticles made from 10 mg/mL solution, which confirms the 
results obtained from DLS.  
To determine whether the BSA nanoparticles remain stable, 
the zeta potential for the two different solutions was measured in 
phosphate-buffered saline (PBS; pH 7.3) for particles created with 
1:1 flow rate ratio (Figure 3a). Generally, zeta potential values 
that are not in the range –30–+30 mV are generally considered to 
have sufficient repulsive force to attain better physical colloidal 
stability.18 From the data obtained, both samples have a relatively 
high zeta potential (–46.1 for 1 mg/mL and –29.2 for 10 mg/mL) 
and are stable in solution. To further elucidate our understanding 
of the nanoparticle formation, an 8-anilinonaphthalene-1-sulfonic 
acid (ANS) assay was conducted. ANS binds to hydrophobic 
cavities found on the protein surface and increases its 
fluorescence intensity upon binding.19 Thus, the more 
hydrophobic residues are exposed on the sample then the higher 
the fluorescence signal. In Figure 3b the fluorescence signal of a 
3 µM BSA solution and a 3 µM nanoparticle based BSA solution 
is shown. The ANS fluorescence showed decreased signal with 
BSA nanoparticles , which indicates that the hydrophobic pockets 
are less exposed in the nanoparticles compared to native BSA. 
This suggests that the interactions between hydrophobic residues 
are driving protein nanoparticle 
formation. 
Typically, when forming protein 
nanoparticles, the use of toxic 
crosslinkers is employed to stabilize 
the system. However, such systems 
can have adverse health effects and 
these crosslinked nanoparticles 
cannot always be used safely for in 
vivo delivery applications. Here, the 
protein was reduced with glutathione 
(GSH) to increase the number of free 
cysteines and promote the formation 
of intermolecular disulfide bridges.12 
To prove the involvement of disulfide 
bridges in the nanoparticle stability, 













Figure 2. BSA nanoparticle characterisation. Protein nanoparticle formation was characterized using two 
different BSA concentrations. (a–c) 1 mg/mL and (d–f) 10 mg/mL solutions were used and characterised with 
(a, b, d and e) DLS and TEM (c and f). Size distributions (a and d) and average size (b and e) were recorded 
for six different flow ratios (ethanol/protein flow rate). And TEM images were taken for (c i and ii) 1 mg and (f 
i and ii) 10 mg/mL BSA nanoparticles with 1:1 flow ratio. 





prepared: BSA, BSA reduced with glutathione (GSH) and BSA in 
which the free cysteine was blocked with 
a cysteine selective carbonylacrylic linker (CAA).20 Total 
conversion from free cysteine to blocked cysteine by using a CAA 
linker was observed (see Figures S3 and S4). All three solutions 
were used to prepare BSA nanoparticles and the stability was 
measured over time in PBS solution (pH 7.2). Initially, the size 
distributions were quite similar, as determined by DLS (Figure 3d). 
However, the differences in stability over time are evident (Figure 
3e). Both BSA and reduced BSA remained as nanoparticles 
throughout the duration of the experiment. However, as expected 
the nanoparticles in which the formation of disulfide bonds was 
blocked disassembled within 24 h. Furthermore, nanoparticles 
made from native BSA showed a decreasing linear trend in 
average size during the stability measurement. This indicates 
lower stability relative to nanoparticles made from reduced 
nanoparticles. 
Following the characterisation of nanoparticles formed by 
using the co-flow, a protein-drug particle was established, with 
potential for clinical application. We chose to use HSA in this 
study since it is the most abundant protein in human plasma and 
therefore widely used for drug delivery.21 Moreover, due to its 
structural similarity to BSA, it could be assumed to work similarly 
to BSA in the co-flow method. Celastrol was chosen as a cargo 
molecule due to its potential as a therapeutic molecule.13 However, 
its use is still limited due to its highly lipophilic nature and 
cytotoxicity. Thus, it would be of significant relevance if this 
molecule could be encapsulated into a more hydrophilic and less 
toxic shell. HSA/celastrol nanoparticles were created by using the 
previously established strategy by co-flowing HSA with celastrol 
in EtOH (Figure 4a). Similarly, to BSA, HSA was partly reduced 
prior to microfluidic co-flow to increase the number of 
intermolecular disulfide bridges and further to increase the 
stability of produced nanoparticles. This time there are two 
contributing factors for nanoparticle 
formation. In addition to the 
desolvating factor of EtOH to protein, 
now the aqueous protein solution is 
desolvating celastrol due to its low 
solubility in water. We were expecting 
celastrol to aggregate due to the 
addition of water and further interact 
with the exposed hydrophobic 
residues of HSA burying the lipophilic 
cargo into a polar shell. If celastrol 
and protein did not interact, we would 
expect to see two populations of 
nanoparticles, which would likely be 
evident in the size distributions 
obtained with DLS. Furthermore, 
amorphous protein and crystalline 
celastrol would have different 
morphologies. Similar to BSA-based 
nanoparticles, the EtOH to protein 
solution ratio was investigated for 
HSA/celastrol co-nanoparticles 
(Figure 4b). Even though the size 
distribution (Figure 4a) was slightly 
broader than in the case of HSA alone, 
only one population was achieved, which suggests an interaction 
between HSA and celastrol. A 4:1 flow rate ratio gave a 
distribution with an average size of 105.0 ± 0.7 nm (PDI = 0.026) 
for HSA and 122.5 ± 0.9 nm (PDI = 0.107) for HSA with celastrol 
(Figure 4a), which are ideal for drug delivery purposes.1 
Furthermore, similarly to the BSA-based nanoparticles (Figures 
2c and 2f), the produced HSA/celastrol particles were spherical 
as determined from the TEM micrographs (Figure 4d). However, 
the higher contrast in the TEM images suggests higher density of 
the nanoparticles than in case of pure BSA nanoparticles. This 
could be due to the addition of celastrol inside the nanoparticle 
matrix. To quantify the amount of encapsulated celastrol and get 
an estimate of the encapsulation efficiency (EE%), HPLC was 
used. An EE% of 75 ± 24 % was achieved by comparing the 
amount of celastrol injected in the co-flow device to the amount 
free in solution after nanoparticle formation. 
In addition to encapsulation, the release kinetics of the cargo 
molecules is important for drug delivery applications. The release 
should not happen before the nanoparticle has reached its target. 
The release profiles of celastrol were followed by using HPLC. 
Two experiments were conducted: in the first, the nanoparticles 
were placed in PBS (pH 7.3) and in the second experiment, the 
nanoparticles were mixed with 10% human serum for 24 h 
(Figure 4e). The release kinetics for both samples follows the 
same trend over a 10 h period reaching »10% release, but after 
24 h the celastrol concentration in the solution drops to 0 in the 
sample containing human serum. This could mean either that the 
celastrol concentration is too high and it forms aggregates, which 
are then not detected, or that celastrol is not stable in human 
serum. Finally, the cell toxicity of free celastrol and HSA/celastrol 
 
Figure 3. Stability of BSA nanoparticles. (a) Zeta potential measurement for nanoparticles made from 1 and 
10 mg/mL BSA solutions by using a 1:1 flow ratio (ethanol/water). (b) ANS binding to free BSA and BSA 
nanoparticles. (c) Stability in aqueous solution (PBS, pH 7.3) was examined with three different samples: 
native BSA (BSA, blue), BSA with blocked free cysteine (BSA+CAA, orange) and GSH reduced BSA 
(BSA+GSH, green). (d) Size distributions for these three samples following their formation by using the co-
flow method and (e) average diameter after 1,2 and 3 days of incubation in 23 ± 2 ºC. The error bars in panel 
e represent the standard deviations of the size distributions. 





nanoparticles were examined (Figure 4f) and show high toxicity 
with free celastrol with an EC50 of 125 ± 34 nM. However, when 
celastrol is encapsulated within HSA nanoparticles its toxicity is 
greatly reduced (EC50 approximately 1600 nM). Indeed, using 
encapsulated celastrol, a dose 10 times higher can be tolerated 
by cells. Cell toxicity is an important consideration for biomedical 
applications and should be minimized in order to reduce potential 
side effects that occur as a result off targeted interactions with 
healthy cells. Even with the best available targeting strategies 
only portion of the injected drug molecules end up in the target 
tissue. Thus, reducing the cytotoxicity of a drug significantly 
decreases potential side effects.
 
Figure 4. Production of HSA/celastrol hybrid nanoparticles. (a) Celastrol is encapsulated within HSA nanoparticles by the microfluidic co-flow device. This was 
achieved by adding celastrol to the EtOH phase and HSA as the protein phase. (b) TEM micrographs of HSA/celastrol nanoparticles formed by using a 4:1 flow 
rate ratio (EtOH/protein). (c) The resulting hybrid nanoparticles have slightly broader size distributions. (d) The average diameter sizes were comparable to those 
of pure HSA nanoparticles. (e) Stability of HSA/celastrol nanoparticles in PBS and in 10 % human serum, followed over a 24 h time period. The release of celastrol 
from the nanoparticles to the outside environment was determined by HPLC. (f) Cell viability in RAW 264.7 murine macrophages with different concentrations of 
celastrol, either free in solution or incorporated into HSA nanoparticles.
Protein nanoparticles have gained considerable attention 
owing to their high binding capacity of various drugs and low 
immunogenic response, which minimises adverse side-effects. 
Here, a microfluidic platform for generating protein nanoparticles 
for drug delivery was presented. A microfluidic co-flow method 
was established in which sub-micrometre-sized protein particles 
were created. By using this co-flow method, HSA nanoparticles 
were formed with homogeneous size distribution and we showed 
that by varying the flow rates of the different components, the 
average size of the nanoparticles can be modulated from »100 
nm to 1 µm. The nanoparticles were stabilized by intramolecular 
disulfide bonds by reducing HSA prior to co-flowing and by giving 
them time to re-oxidise after the co-flow, which eliminates the 
need for toxic crosslinkers. We further demonstrate that highly 
lipophilic celastrol can be encapsulated into our nanoparticles, 
which increases its solubility in aqueous solutions and decreases 
its cell toxicity. Future work will determine the potential of these 
particles for targeted drug-delivery.  
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We demonstrate a microfluidic co-flow device to produce drug loaded albumin 
nanoparticles without additional crosslinking steps. This method showed high 
loading efficiency of the lipophilic drug celastrol, which created spherical 
nanoparticles with considerable reduced drug cytotoxicity. 
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